drugset / Trial / NCT04199169
Safety and Immunogenicity of a Nipah Virus Vaccine
Phase 1
Completed
192 enrolled
Auro Vaccines LLC
Children's Hospital Medical Center, Cincinnati · collabCoalition for Epidemic Preparedness Innovations · collabPATH · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
A first-in-human, phase 1 trial is to be conducted in a healthy adult population in the US to assess the safety and immunogenicity of three ascending Nipah vaccine (HeV-sG-V; Hendra virus soluble glycoprotein vaccine) dosages. Different dosing regimens and number of doses will also be explored.
Timeline
- Start
- 2020-02-18
- Primary completion
- 2022-05-06
- Completion
- 2022-05-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HeV-sG-V | Vaccine | 10 ug | — |
| Subject | HeV-sG-V | Vaccine | 30 ug | — |
| Subject | HeV-sG-V | Vaccine | 100 ug | — |